These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10325516)

  • 1. The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials.
    Crawford ED
    Eur Urol; 1999; 35(5-6):511-4. PubMed ID: 10325516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
    Crawford ED; DeAntoni EP; Ross CA
    J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of prostate cancer: concepts and strategies.
    Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovitch L; Malone WA; Crowell JA; Sigman CC
    Eur Urol; 1999; 35(5-6):342-50. PubMed ID: 10325487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
    Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
    J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target populations, pathological biomarkers and chemopreventive agents in prostate cancer prevention.
    Montironi R; Barbisan F; Mazzucchelli R
    Arch Ital Urol Androl; 2003 Sep; 75(3):127-34. PubMed ID: 14661390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
    Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
    Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report.
    Cyrus-David MS; Weinberg A; Thompson T; Kadmon D
    J Urol; 2005 Jun; 173(6):1923-5. PubMed ID: 15879782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA velocity and PSA slope.
    Benecchi L
    Prostate Cancer Prostatic Dis; 2006; 9(2):169-72. PubMed ID: 16568147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study.
    Johansson M; Holmström B; Hinchliffe SR; Bergh A; Stenman UH; Hallmans G; Wiklund F; Stattin P
    Int J Cancer; 2012 Jan; 130(1):129-37. PubMed ID: 21328341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
    Bostwick DG; Aquilina JW
    J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial.
    Auvinen A; Määttänen L; Finne P; Stenman UH; Aro J; Juusela H; Rannikko S; Tammela TL; Hakama M
    Int J Cancer; 2004 Oct; 111(6):940-3. PubMed ID: 15300807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostatic specific antigen in practice in 1997].
    Salomon L; Colombel M; Patard JJ; Chopin D; Abbou CC
    Ann Urol (Paris); 1998; 32(2):69-72. PubMed ID: 9599634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current biomarkers for diagnosing of prostate cancer.
    Stephan C; Jung K; Ralla B
    Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rational basis for chemoprevention of prostate cancer.
    Huang CJ; Baum ML
    Am J Bioeth; 2011 Dec; 11(12):27-9. PubMed ID: 22146027
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemoprevention strategies for prostate cancer.
    Bosland MC; McCormick DL; Melamed J; Walden PD; Zeleniuch-Jacquotte A; Lumey LH
    Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S18-27. PubMed ID: 12570331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forfeited health: response to open peer commentaries on "What's wrong with chemoprevention of prostate cancer?".
    Justman S
    Am J Bioeth; 2011 Dec; 11(12):W1-2. PubMed ID: 22146047
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate-specific antigen and other serum and urine markers in prostate cancer.
    Stephan C; Ralla B; Jung K
    Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.